부산대학교 도서관

Background: Dengue infection is distributed throughout the tropical areas around the world, including Indonesia. Dengue fever/ dengue hemorrhagic fever is a mosquito- borne disease caused by dengue virus of any serotype 1 (DEN1) to DEN4. Until now, therapy is based on pathophysiology. Aims: To evaluate the effi cacy and safety of MAC for the treatment of dengue infection. Methods: This clinical trial phase III was designed to study the inhibitory property of MAC against dengue virus (DENV) activity. A double-blind, randomized, controlled trial method was approved by Ethical Committee of Dr. Soetomo Hospital. This study was conducted from January 2012 to November 2013. After a signed informed consent, 530 patients, fever on day-1 or day-2, suspected dengue infection according to WHO criteria, showed positive result either by NS-1, and or IgM - IgG, were recruited. The subjects were divided into 2 groups. Group I received WHO standard treatment and 300 mg - MAC twice daily orally for 7 days. Group II received WHO standard treatment only. History, physical examination and complete blood count were done every day. Laboratory test (liver function, kidney function, CD4, CD8, VCAM, viral load) were performed on the fi rst, fourth and seventh day. Results: The results showed that the quantity of virus signifi cantly decreased in the treatment group (96.67%) compared to the control group (44.79%). Also showed that MAC did improve the immune system by increasing the value of CD8 (6.89%) and CD4 (9.95%). MAC provision does not interfere with the function of liver and kidney, and was well tolerated by the patients. Conclusions: MAC has signifi cant reduction of viral load level, may have immunomodulatory effects, prevent the plasma leakage, no hepatotoxic and nephrotoxic effects. MAC effi cacy as an antiviral agent against DENV infection has been very effectively illustrated.